Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 906349, 10 pages
http://dx.doi.org/10.1155/2015/906349
Clinical Study

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

1Translational Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
2Biostatistics, Celgene Corporation, 33 Technology Drive, Warren, NJ 07059, USA

Received 26 September 2014; Accepted 10 January 2015

Academic Editor: Marco Antonio Velasco-Velázquez

Copyright © 2015 Peter H. Schafer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. D. Gladman, C. Antoni, P. Mease, D. O. Clegg, and P. Nash, “Psoriatic arthritis: epidemiology, clinical features, course, and outcome,” Annals of the Rheumatic Diseases, vol. 64, supplement 2, pp. ii14–ii17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Lowes, A. M. Bowcock, and J. G. Krueger, “Pathogenesis and therapy of psoriasis,” Nature, vol. 445, no. 7130, pp. 866–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Schafer, “Apremilast mechanism of action and application to psoriasis and psoriatic arthritis,” Biochemical Pharmacology, vol. 83, no. 12, pp. 1583–1590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Schett, V. S. Sloan, R. M. Stevens, and P. Schafer, “Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases,” Therapeutic Advances in Musculoskeletal Disease, vol. 2, no. 5, pp. 271–278, 2010. View at Publisher · View at Google Scholar
  5. P. H. Schafer, A. Parton, A. K. Gandhi et al., “Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis,” British Journal of Pharmacology, vol. 159, no. 4, pp. 842–855, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. H. Schafer, A. Parton, L. Capone et al., “Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity,” Cellular Signalling, vol. 26, no. 9, pp. 2016–2029, 2014. View at Publisher · View at Google Scholar
  7. F. E. McCann, A. C. Palfreeman, M. Andrews et al., “Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis,” Arthritis Research and Therapy, vol. 12, no. 3, article R107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. B. Gottlieb, B. Strober, J. G. Krueger et al., “An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast,” Current Medical Research and Opinion, vol. 24, no. 5, pp. 1529–1538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. B. Gottlieb, R. T. Matheson, A. Menter et al., “Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study,” Journal of Drugs in Dermatology, vol. 12, no. 8, pp. 888–897, 2013. View at Google Scholar · View at Scopus
  10. A. Kavanaugh, P. J. Mease, J. J. Gomez-Reino et al., “Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1020–1026, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Kavanaugh, P. J. Mease, A. Adebajo et al., “Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis,” in Proceedings of the Annual Congress of the European League Against Rheumatism, Madrid, Spain, June 2013.
  12. OTEZLA, [package insert], Summit, NJ, USA, Celgene Corporation, September 2014.
  13. D. T. Felson, J. J. Anderson, M. Boers et al., “American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 6, pp. 727–735, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Kane, M. Gogarty, J. O'Leary et al., “Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate,” Arthritis & Rheumatism, vol. 50, no. 10, pp. 3286–3295, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. W. R. van Kuijk, P. Reinders-Blankert, T. J. M. Smeets, B. A. C. Dijkmans, and P. P. Tak, “Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment,” Annals of the Rheumatic Diseases, vol. 65, no. 12, pp. 1551–1557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Deeva, S. Mariani, C. De Luca et al., “Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease,” Cytokine, vol. 49, no. 2, pp. 163–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Szodoray, P. Alex, C. M. Chappell-Woodward et al., “Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system,” Rheumatology, vol. 46, no. 3, pp. 417–425, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Mease, “Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis,” Rheumatology and Therapy, vol. 1, no. 1, pp. 1–20, 2014. View at Publisher · View at Google Scholar
  19. R. R. Keijsers, I. Joosten, P. E. van Erp, H. J. Koenen, and P. C. van de Kerkhof, “Cellular sources of IL-17 in psoriasis: a paradigm shift?” Experimental Dermatology, vol. 23, no. 11, pp. 799–803, 2014. View at Publisher · View at Google Scholar
  20. A. Johnston, Y. Fritz, S. M. Dawes et al., “Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation,” Journal of Immunology, vol. 190, no. 5, pp. 2252–2262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. I. B. McInnes, P. J. Mease, B. Kirkham et al., “Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing,” in Proceedings of the Annual Meeting of the American College of Rheumatology, Boston, Mass, USA, November 2014.
  22. S. J. Pedersen, M. L. Hetland, I. J. Sørensen, M. Østergaard, H. J. Nielsen, and J. S. Johansen, “Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors,” Clinical Rheumatology, vol. 29, no. 11, pp. 1301–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Mastroianni, E. Minutilli, A. Mussi et al., “Cytokine profiles during infliximab monotherapy in psoriatic arthritis,” British Journal of Dermatology, vol. 153, no. 3, pp. 531–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Kanelleas, C. Liapi, A. Katoulis et al., “The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept,” Clinical and Experimental Dermatology, vol. 36, no. 8, pp. 845–850, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. U. M. Vischer and C. B. Wollheim, “Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis,” Blood, vol. 91, no. 1, pp. 118–127, 1998. View at Google Scholar · View at Scopus
  26. U. M. Vischer, “Von Willebrand factor, endothelial dysfunction, and cardiovascular disease,” Journal of Thrombosis and Haemostasis, vol. 4, no. 6, pp. 1186–1193, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. N. D. Di Minno, S. Iervolino, R. Peluso, A. Di Minno, P. Ambrosino, and R. Scarpa, “Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis—effect of different treatments,” The Journal of Rheumatology, vol. 41, no. 4, pp. 714–722, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Taylan, I. Sari, D. L. Kozaci et al., “Evaluation of various endothelial biomarkers in ankylosing spondylitis,” Clinical Rheumatology, vol. 31, no. 1, pp. 23–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. C. L. Wagner, S. Visvanathan, M. Elashoff et al., “Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab,” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 83–88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Chandran, H. Shen, R. A. Pollock et al., “Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis,” The Journal of Rheumatology, vol. 40, no. 6, pp. 866–871, 2013. View at Publisher · View at Google Scholar · View at Scopus